We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

142 hedge funds and large institutions have $428M invested in Progenics Pharmaceuticals Inc in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 41

0% more capital invested

Capital invested by funds: $426M → $428M (+$2.07M)

7% less funds holding

Funds holding: 152 → 142 (-10)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

35% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $2.78M

Holders
142
Holders Change
-10
Holders Change %
-6.58%
% of All Funds
3.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
55
Reduced
41
Closed
23
Calls
$1.81M
Puts
$2.78M
Net Calls
-$973K
Net Calls Change
-$607K

Top Buyers

Rank Fund Capital Flow
1
AAP
Ardsley Advisory Partners
Connecticut
+$8.89M
2
BlackRock
BlackRock
New York
+$1.3M
3
HP
Hikari Power
Japan
+$1.27M
4
TCIM
TIAA CREF Investment Management
New York
+$1.21M
5
Bank of America
Bank of America
North Carolina
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$6.79M
2
PWAM
Park West Asset Management
California
-$6.16M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.54M
4
Invesco
Invesco
Georgia
-$3.34M
5
State Street
State Street
Massachusetts
-$2.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$78.1M -$1.86M -293,297 -3%
BlackRock
2
BlackRock
New York
$72.1M +$1.3M +203,989 +2%
EAM
3
Eagle Asset Management
Florida
$32.2M +$982K +154,553 +4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$32.2M +$448K +70,543 +2%
State Street
5
State Street
Massachusetts
$24.4M -$2.49M -392,545 -11%
BBA
6
Baker Bros. Advisors
New York
$23.2M – – –
Fidelity Investments
7
Fidelity Investments
Massachusetts
$18M -$1.42M -223,040 -8%
PA
8
Pinnacle Associates
New York
$17.6M -$445K -70,085 -3%
AAP
9
Ardsley Advisory Partners
Connecticut
$14.1M +$8.89M +1,400,000 +275%
RHJA
10
Rice Hall James & Associates
California
$9.68M -$317K -49,936 -4%
RA
11
Royce & Associates
New York
$9.46M -$391K -61,600 -5%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$7.79M -$84K -13,220 -1%
Northern Trust
13
Northern Trust
Illinois
$6.53M -$56.2K -8,842 -1%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.44M -$363K -57,089 -9%
Principal Financial Group
15
Principal Financial Group
Iowa
$4.33M -$38.7K -6,095 -1%
Bank of America
16
Bank of America
North Carolina
$4.29M +$1.1M +173,589 +42%
TCIM
17
TIAA CREF Investment Management
New York
$3.49M +$1.21M +190,906 +67%
Fuller & Thaler Asset Management
18
Fuller & Thaler Asset Management
California
$3.27M -$13.3K -2,100 -0.5%
Deutsche Bank
19
Deutsche Bank
Germany
$2.82M -$2M -314,474 -45%
Ameriprise
20
Ameriprise
Minnesota
$2.68M -$19.2K -3,027 -0.8%
Charles Schwab
21
Charles Schwab
California
$2.37M +$99K +15,581 +5%
NI
22
Numeric Investors
Massachusetts
$2.16M -$828K -130,300 -31%
GC
23
Guggenheim Capital
Illinois
$2.1M +$160K +25,113 +10%
Fisher Asset Management
24
Fisher Asset Management
Washington
$1.85M +$570K +89,808 +55%
CCM
25
Cadence Capital Management
Massachusetts
$1.78M +$310K +48,863 +25%
1
2 3 4 5

PGNX Hedge Fund Activity: Q3 2017 in Review

142 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2017, worth a combined $428M — up 0.49% from $426M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of PGNX and 15 opened new positions — a net loss of 8 holders — while 41 trimmed existing stakes and 55 added.

The largest buyer was Ardsley Advisory Partners, adding an estimated $8.89M. The largest seller was Broadfin Capital, exiting entirely with an estimated $6.79M sold.

  • 142 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2017, down from 152 in Q2 2017.
  • Funds reported $428M of Progenics Pharmaceuticals Inc stock for Q3 2017, up 0.49% quarter-over-quarter.
  • 15 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2017 and 23 closed out, a net change of -8 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2017 was Ardsley Advisory Partners, an estimated $8.89M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2017 was Broadfin Capital, an estimated $6.79M sold.

Based on aggregated 13F filings for Q3 2017.